Please use this identifier to cite or link to this item:
Title: A comparative study between real-time PCR and loop-mediated isothermal amplification to detect carbapenemase and/or ESBL genes in Enterobacteriaceae directly from bronchoalveolar lavage fluid samples
Author: Vergara, A.
Moreno-Morales, J.
Roca, I
Pitart, Cristina
Kostyanev, T.
Rodriguez-Bano, J.
Goossens, H.
Marco, F.
Vila Estapé, Jordi
Keywords: Diagnòstic microbiològic
Aparell respiratori
Diagnostic microbiology
Respiratory organs
Issue Date: 1-Jun-2020
Publisher: Oxford University Press
Abstract: Objectives: To evaluate and compare the efficacy of real-time PCR (Xpert Carba-R) and loop-mediated isothermal amplification (Eazyplex® SuperBug CRE) for detecting carbapenemase carriage in Enterobacteriaceae directly from bronchoalveolar lavage (BAL). Methods: Negative BAL samples were spiked with 21 well-characterized carbapenemase-producing Enterobacteriaceae strains to a final concentration of 102-104 cfu/mL. Xpert Carba-R (Cepheid, Sunnyvale, CA, USA), which detects five targets (blaKPC, blaNDM, blaVIM, blaOXA-48 and blaIMP-1), and the Eazyplex® SuperBug CRE system (Amplex-Diagnostics GmbH, Germany), which detects seven genes (blaKPC, blaNDM, blaVIM, blaOXA-48, blaOXA-181, blaCTXM-1 and blaCTXM-9), were evaluated for the detection of these genes directly from BAL samples. Results: Xpert Carba-R showed 100% agreement with carbapenemase characterization by PCR and sequencing for all final bacteria concentrations. Eazyplex® SuperBug CRE showed 100%, 80% and 27% agreement with PCR and sequencing when testing 104, 103 and 102 cfu/mL, respectively. False negative results for Eazyplex® SuperBug CRE matched the highest cycle threshold values for Xpert Carba-R. Hands-on time for both assays was about 15 min, but Eazyplex® SuperBug CRE results were available within 30 min, whereas Xpert Carba-R took around 50 min. Conclusions: We here describe the successful use of two commercial diagnostic tests, Xpert Carba-R and Eazyplex® SuperBug CRE, to detect bacterial carbapenem resistance genes directly in lower respiratory tract samples. Our results could be used as proof-of-concept data for validation of these tests for this indication.
Note: Versió postprint del document publicat a:
It is part of: Journal of Antimicrobial Chemotherapy, 2020, vol. 75, num. 6, p. 1453-1457
Related resource:
ISSN: 0305-7453
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
707110.pdf1.08 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.